Donald Trump has threatened sweeping new trade measures on the pharma sector unless manufacturers commit to producing in the US.

Sanofi has committed $625m to its corporate venture capital arm, Sanofi Ventures, for funding biotech and digital health companies.

Pfizer is claiming a space in the global obesity market as it announces plans to acquire weight loss drug developer Metsera for $4.9bn.

Roche is acquiring US-based biotech 89bio in a deal worth up to $3.5 billion, bolstering its pipeline with a late-stage therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

Phesi analysis shows GLP-1 therapies moving beyond diabetes and obesity into 100+ diseases, from cancer to cardiovascular conditions.

The latest ABPI and PwC Pharmaceutical Competitiveness Framework reveals the UK is losing ground in pharma R&D, investment, and clinical trials, with rankings slipping sharply since 2018.

Novo Nordisk announces 9,000 job cuts to streamline operations and reinvest in diabetes and obesity growth, aiming for long-term efficiency.